CD229在浆细胞疾病免疫分型中的应用价值  

Application of CD229 in immunophenotyping of plasma cell diseases

作　　者：张义炜 吴英理[1] 贺明[1] ZHANG Yiwei;WU Yingli;HE Ming(Department of Pathology and Physiology,Key Laboratory of Cell Differentiation and Apoptosis,ShanghaiJiaotong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院细胞分化与凋亡教育部重点实验室病理生理学教研室

出　　处：《检验医学》2019年第7期605-609,共5页Laboratory Medicine

基　　金：国家自然科学基金（81470841）;上海市浦江人才计划资助项目（16PJ1405400)

摘　　要：目的探讨CD229作为新的流式细胞术(FCM)浆细胞设门标志物的可行性。方法选取150例患者,其中浆细胞疾病110例、非血液病患者40例。采用FCM分析患者骨髓中浆细胞及其他细胞(淋巴细胞、粒细胞和单核细胞)CD229、CD138和CD38的表达并作比较,同时比较不同设门组合得出的浆细胞百分比。结果浆细胞CD229、CD138和CD38的平均荧光强度(MFI)分别为25.54(10.01~68.34)、30.59(4.77~88.94)和67.04(18.57~98.26),CV分别为69.2%(30.9%~110.4%)、96.5%(38.4%~221.0%)和42.8%(31.5%~110.2%)。浆细胞CD229的MFI明显高于其他细胞(P<0.05)。Pearson相关分析显示,CD229+CD38+CD45和CD229+CD45这2种设门组合得到的总浆细胞百分比与欧洲骨髓瘤网络(EMN)推荐的参考设门组合(CD38+CD45+CD138)呈明显正相关(r值分别为0.98、0.94,P<0.05)。异常浆细胞CD229的MFI与正常浆细胞比较差异有统计学意义(P<0.05)。结论CD229是一种可靠的浆细胞设门抗体,可弥补CD38及CD138设门组合的不足,同时还能用于判断浆细胞的性质。Objective To evaluate the utility of CD229 as a new flow cytometry(FCM)plasma cell gating marker in immunophenotyping.Methods The expression of CD229 was determined in 150 patients(110 cases of plasma cell diseases and 40 cases of non-blood diseases),which was compared with CD138 and CD38 expressions on plasma cell and other hematopoietic cells(lymphocyte,granulocyte and monocyte).The plasma cell percentages obtained by different gating strategies were compared.Results The mean fluorescence intensities(MFI)of CD229,CD138 and CD38 were 25.54(10.01-68.34),30.59(4.77-88.94)and 67.04(18.57-98.26),respectively,and the coefficients of variation(CV)were 69.2%(30.9%-110.4%),96.5%(38.4%-221.0%)and 42.8%(31.5%-110.2%).The MFI of CD229 on plasma cell was stronger than those on other hematopoietic cells(P<0.05).Pearson correlation analysis showed that plasma cell percentages using CD229+CD38+CD45 and CD229+CD45 revealed positive correlation with a reference gating strategy using CD38+CD45+CD138 recommended by European Myeloma Network(EMN)(r=0.98 and 0.94,P<0.05).The MFI of CD229 between abnormal plasma cell and normal plasma cell had statistical significance(P<0.05).Conclusions CD229 is a reliable plasma cell gating marker.It can make up for the deficiency of the combination of CD38 and CD138 and also can be used to judge the characteristic of plasma cells.

关 键 词：CD229 免疫分型 浆细胞疾病 

分 类 号：R446.1[医药卫生—诊断学]